Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Rituximab in Patients With Refractory Primary Membranous Nephropathy

NCT03880643 is registered in ClinicalTrials.gov with Istanbul University as lead sponsor.

NCT NCT03880643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03880643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Rituximab in Patients With Refractory Primary Membranous Nephropathy
Lead sponsor
Istanbul University
Phase
Observational
Overall status
Completed
Start date
November 1, 2018
Completion date
September 30, 2019
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glomerulonephritis, membranous